Contact us to place a job advertisement on this page
Join the BPS Job Alert eGroup to get automated job updates delivered directly to your inbox as soon as we have them
MRC Doctoral Training Programme Studentship, University of Glasgow, Glasgow, Scotland
Membership Engagement and Development Manager, Campaign for Science and Engineering (CaSE)
Faculty for the Department of Pharmacology, American University of Antigua
Director, Translational Medicine & Clinical
The British Journal of Clinical Pharmacology (BJCP) has the primary goal of publishing high quality research on all aspects of drug action in humans. The journal has a wide readership, bridging the medical profession, clinical research and the pharmaceutical industry, and is published monthly. BJCP is owned by the British Pharmacological Society (BPS) and published by Wiley-Blackwell.
BPS is seeking to appoint a new Editor-in-Chief to succeed Professor Jim Ritter who will complete a full term at the end of 2014. The Editor-in-Chief will be responsible for continuing to improve the quality of BJCP, and driving new initiatives for the journal. The Editor-in-Chief will deliver strategic direction to the journal, and contribute more broadly to BPS’ publication strategy.
The deadline for applications is Friday 16 May and we will hold interviews on Thursday 26 June.
Project title: Suppression of IL-6 signalling by BMP4: a "missing link" in the development of pulmonary arterial hypertension?
Supervisors: Dr Tim Palmer and Professor Mandy MacLean
Project Summary: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature. Heritable PAH is associated with haploinsuffiency of the bone morphogenetic protein receptor II (BMPRII) leading to pulmonary vascular remodelling. Current therapeutic options simply relieve symptoms such as breathlessness, and so there is an urgent need to identify processes that could be targeted pharmacologically to arrest and/or reverse disease progression. Our original hypothesis is that one important consequence of defective BMP4/BMPR-II signalling is a reduced ability to inhibit IL-6-mediated trans-signalling in the pulmonary vasculature via induction of "suppressor of cytokine signaling 3" (SOCS3), and that this contributes to the chronic pulmonary inflammation observed in PAH. To test this hypothesis, the student will pursue an integrated programme of work that brings together the complimentary expertise of the two supervisors. This will involve A) Identifying the signalling pathways and transcription factors responsible for BMP4-mediated induction of SOCS3, B) Assessing IL-6 responses in pulmonary vascular cells from control and PAH patients, and C) Examining the translational potential of these findings using established in vivo models of PAH in mice in which IL-6 signalling complexes have been rendered resistant to inhibition by SOCS3.
Training: The project will provide opportunities for inter-disciplinary training in molecular cell biology and cutting edge technologies to examine cell signalling networks, as well providing training in cardiovascular physiology and in vivo whole animal research techniques. This will be supported by an extensive generic and transferable skills training programme provided by the College of Medical, Veterinary and Life Sciences Graduate School.
The studentship will be carried out within the Institute of Cardiovascular and Medical Sciences, which was recently designated as a BHF Centre of Excellence due to the outstanding training environment and opportunities for collaborative translational research.
Details: This is a fully funded 3.5-year PhD studentship commencing in October 2014. Applicants will normally be expected to reside (or have residency) within the UK. EU nationals will have to demonstrate that they have spent the three years prior to application resident in the UK (this can include residence whilst undertaking undergraduate study). Applicants should have obtained, or expect to obtain a 2:1 or 1st class Honours degree in Biochemistry, Pharmacology or a related subject. The financial package will include a 3.5 year stipend (currently £13,726 per annum), approved University fees, Research Training Support Grant and a conference allowance.
Interested students should contact Dr. Tim Palmer (Tim.Palmer@glasgow.ac.uk) for more information in the first instance.
The pharmacology related coursework introduces the student to the scientific basis for the use of drugs in medical practice and the essential principles of clinical pharmacology. The courses concentrate on selected prototype drugs and on general pharmacologic principles that govern the action of all drugs on the body. This is a teaching position of second year medical students within an integrated, systems-based basic science curriculum.
About AUA: American University of Antigua was chartered in 2004 by a group of renowned American physicians and medical education professionals to address the shortage of healthcare professionals faced in the US. In order to address this shortage, AUA is dedicated to breaking down the barriers that have prevented underrepresented minorities from obtaining a medical education, and subsequent licensure, in the US. www.auamed.org As the only hospital-integrated medical program in the Caribbean, AUA has graduated over 1000 licensed physicians in the United States and Canada. Located on the island of Antigua, in the Eastern Caribbean, our new $60-million, 17-acre campus with over 75,000 sq. ft. of Wi-Fi enabled classrooms is a testament to our vision and long term pledge to provide the most comprehensive learning facility in the Caribbean. Visit the Official website of Antigua, Barbuda.
About the Opportunity: The mission of AUA College of Medicine is to provide the student with an excellent education that is compatible to the instruction provided at the best US medical schools. The pharmacology curriculum is designed to provide students with the knowledge and skills necessary to prepare them to successfully practice medicine in the US. AUA’s students are highly diverse, representing many international backgrounds. This is a unique opportunity to influence the future of medicine and medical care within the US while living and working at our basic sciences campus on the Caribbean island of Antigua earning a competitive potentially tax exempt income. This position requires a one-year commitment and has a targeted start date of August 2014 or sooner.
Compensation & Title: Commensurate with education and experience.
1. 1. Ph.D. or PharmD, related biomedical fields with a minor in Physiology (desirable)
2. Demonstrated ability to communicate effectively with students, faculty and administration
3. Two plus years of experience in a similar position within the US, Canada or UK institution of higher education or medical training
Applications including a CV, Cover letter and compensation requirements should be submitted via e-mail. Subject line should read: Pharma – Applicant Name
ABOUT CaSE: The Campaign for Science and Engineering (CaSE) is the leading independent advocate for science and engineering in the UK. Our mission is to raise the political profile of science and engineering by conveying its economic and cultural importance. The strength of our policy advocacy is due to our political networks, independent analysis, broad membership, and responsiveness. We have an excellent track record of influencing policy and media at the highest levels, and focusing on the important and exciting issues facing the science and engineering sector in the UK. We want the UK to have world-leading research and education, skilled scientists and engineers, and innovative businesses. CaSE is a membership organisation funded by around 750 individual members and 100 organisations including industry, universities, learned and professional bodies, and research charities that recognise the importance of science and engineering for the UK.
ABOUT THE ROLE: What the role offers Now is an exciting time to join CaSE as our Membership Engagement and Development Manager. CaSE and its Board are committed to a new drive to expand our membership and develop engagement with our members as one of our highest priority objectives. You will design and implement CaSE’s membership strategy to deliver this objective, giving you the chance to really own and deliver a successful strategy. CaSE will provide you with access to mentoring from a senior membership professional to support you in your role and for your professional development. This role offers unrivalled access and exposure to a high profile network of leading figures from industry and academia in the science and engineering sector. What the role requires We are looking for someone who is enthusiastic, takes initiative, can think strategically and is highly organised.
More details including how to apply can be found on the CaSE website.
The deadline for applications is 11 May 2014.
Jim Gleeson at CK Clinical is recruiting for a Director, Translational Medicine & Clinical Pharmacology for a permanent position with a successful and dynamic international pharmaceutical company. The position will be based at their offices in the Home Counties.
Responsibilities: As the Director, Translational Medicine & Clinical Pharmacology your role will be to lead the early clinical development project team and to represent that team both internally and externally.
Specific duties will include:
Qualifications: As the Director, Translational Medicine & Clinical Pharmacology, you will require the following:
For more information or to apply for this Director, Translational Medicine & Clinical Pharmacology position please contact Jim Gleeson or call +44 (0)1438 842973. Alternatively please apply online now. CK Clinical is an Equal Opportunities employer and welcomes applications from all who meet our selection criteria. If you do not hear back from us within five working days of your application for this role, it means that on this occasion you have not been shortlisted for the next stage of the recruitment campaign.
Entitlement to work in the EEA is essential. Please quote reference CL28364 in all correspondence.